{"id":8126,"date":"2026-09-25T15:06:46","date_gmt":"2026-09-25T13:06:46","guid":{"rendered":"https:\/\/value-dossier.com\/?p=8126"},"modified":"2026-09-25T16:16:19","modified_gmt":"2026-09-25T14:16:19","slug":"a-fundamental-shift-in-german-market-access-rebate-contracts-for-patent-protected-medicines","status":"publish","type":"post","link":"https:\/\/value-dossier.com\/en\/a-fundamental-shift-in-german-market-access-rebate-contracts-for-patent-protected-medicines\/","title":{"rendered":"A Fundamental Shift in German Market Access: Rebate Contracts for Patent-Protected Medicines"},"content":{"rendered":"\n<section class=\"wrap_outer textblock\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"okd-text\">\n            <p>&nbsp;<\/p>\n<p>With the German Health Insurance Contribution Rate Stability Act (BStabG) now in force, statutory health insurances can establish cross-molecule rebate contracts for clusters of innovative, patent-protected medicines under \u00a7130e SGB<\/p>\n<p>For manufacturers, the implications are significant:<\/p>\n<ul>\n<li>Intensified price competition in form of tender business for patent-protected products in certain indications<\/li>\n<li>AMNOG benefit assessment and value-based pricing is augmented by potential exclusive agreements<\/li>\n<li>Prescription management will be organized based on rebate contracts<\/li>\n<li>A new strategic imperative: The new framework requires action for manufacturers who want to protect or gain market shares.<\/li>\n<\/ul>\n<p>What should manufacturers do now?<\/p>\n<ul>\n<li>Understand market shares, competitors, price structures and prescribing patterns separately for each indication<\/li>\n<li>Systematically analyze therapeutic comparability in the indication<\/li>\n<li>Closely monitor the activities of the Statutory Health Insurance companies<\/li>\n<li>Prepare for potential tender strategies<\/li>\n<\/ul>\n<p>Germany&#8217;s reimbursement landscape is changing rapidly, and early preparation will be critical.<\/p>\n        <\/div>\n\n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":8127,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nicht-kategorisiert"],"acf":[],"_links":{"self":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/8126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/comments?post=8126"}],"version-history":[{"count":2,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/8126\/revisions"}],"predecessor-version":[{"id":8135,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/8126\/revisions\/8135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media\/8127"}],"wp:attachment":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media?parent=8126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/categories?post=8126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/tags?post=8126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}